Effect of Danshao Huaxian capsule on expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in fibrotic liver of rats

Table 1 Liver index, serum HA, and ALT in rats of each group (mean±SD)

Group	n	Liver index (relative liver weight)	HA (ng/mL)	ALT (U/L)
A	16	0.0249±0.0027	192.52±41.97	32.40±2.30
B	12	0.0423±0.0044b	316.17±78.48a	174.50±6.02b
C	10	0.0295±0.0019bd	300.86±72.73a	104.75±6.54bd
D	10	0.0268±0.0028de	224.92±36.62ce	96.13±4.94de
E	10	0.0267±0.0017df	200.78±31.71ce	93.13±5.79df

^aP<0.05,

^bP<0.01 vs normal control group;

^cP<0.05,

^dP<0.01 vs hepatic fibrosis group;

^eP<0.05,

^fP<0.01 vs non-DSHX-treated group.

Table 2 Degree of hepatic fibrosis in rats of each group

Group	n	Degree of hepatic fibrosis
		0	I	II	III	IV	V	Average
A	16	16	0	0	0	0	0	0
B	12	0	0	0	1	7	4	4.25d
C	10	0	1	4	3	2	0	2.60df
D	10	1	3	5	1	0	0	1.60af
E	10	1	6	2	1	0	0	1.30bf

^aP<0.05 and

^bP<0.01 vs non-DSHX-treated group;

^dP<0.01 vs normal control group;

^fP<0.01 vs hepatic fibrosis group.

Table 3 Urinary excretion of Hyp (μg/24 h) in rats of each group (mean±SD)

Group	n	Urinary excretion of Hyp
A	16	47.80±5.76
B	12	62.00±6.40b
C	10	182.44±30.83b
D	10	242.76±49.76d
E	10	541.09±73.39df

^bP<0.01 vs normal control group;

^dP<0.01 vs hepatic fibrosis group;

^fP<0.01 vs non-DSHX-treated group.

Table 4 Percentage of expression of MMP-1 and TIMP-1 in each group (mean±SD)

Group	n	MMP-1 (%)	TIMP-1 (%)
A	16	0.595±0.87	1.08±0.68
B	12	5.956±1.85f	9.04±1.60f
C	10	5.104±2.20f	6.46±1.77bf
D	10	8.271±3.29ad	5.07±0.69bc
E	10	8.518±1.88ad	4.32±0.63bd

^aP<0.05 and

^bP<0.01 vs the hepatic fibrosis group;

^cP<0.05 and

^dP<0.01 vs non-DSHX-treated group;

^fP<0.01 vs normal control group.